Core Viewpoint - Connoa-B (02162) shares rose nearly 3%, currently up 2.24% at HKD 57, with a trading volume of HKD 19.71 million, following the announcement of CM336's fast track designation by the FDA for treating autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) [1] Group 1 - Connoa and Ouro Medicines Ltd announced that their BCMA×CD3 dual antibody CM336 (OM336) received fast track designation (FTD) from the FDA for the treatment of AIHA and ITP [1] - The fast track designation highlights the urgent need for innovative treatment options for these diseases and underscores the therapeutic potential of CM336 in autoimmune diseases [1] - CM336 has also received orphan drug designation (ODD) from the FDA for the treatment of AIHA and ITP [1] Group 2 - Connoa entered into an exclusive licensing agreement with Ouro Medicines Ltd, granting Ouro exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]

Core Viewpoint - Connoa-B (02162) has seen a nearly 3% increase in stock price, currently trading at 57 HKD, following the announcement of its drug CM336 receiving Fast Track Designation from the FDA for treating autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) [1] Group 1 - Connoa and Ouro Medicines Ltd have jointly announced that their BCMA×CD3 dual antibody CM336 (OM336) has been granted Fast Track Designation by the FDA for the treatment of AIHA and ITP [1] - The Fast Track Designation highlights the urgent need for innovative treatment options for these diseases and underscores the therapeutic potential of CM336 in autoimmune diseases [1] - CM336 has also received Orphan Drug Designation (ODD) from the FDA for the treatment of AIHA and ITP, indicating its significance in addressing rare diseases [1] Group 2 - Connoa has entered into an exclusive licensing agreement with Ouro Medicines Ltd, granting them exclusive rights to research, develop, manufacture, register, and commercialize CM336 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]